| Title |
Use of levosimendan in the treatment of cerebral vascular vasospasm: a case study
|
|---|---|
| Published in |
Drug Design, Development and Therapy, June 2018
|
| DOI | 10.2147/dddt.s158237 |
| Pubmed ID | |
| Authors |
Dariusz Onichimowski, Krzysztof Nosek, Radosław Goraj, Rakesh Jalali, Aleksandra Wińska, Aleksandra Pawlos, Bułat Tuyakov |
| Abstract |
Despite the progress in the management of cerebral arterial aneurysms, subarachnoid hemorrhage (SAH) remains the major cause of neurological disability. While SAH-related deaths usually occur as a result of brain impairment due to hemorrhage, permanent neurological deficits are caused by cerebral ischemia due to edema and spasm of cerebral arteries. Additionally, ~20%-30% of patients with SAH develop secondary cardiomyopathy; this phenomenon is known as neurogenic stress cardiomyopathy (NSC), which is associated with increased mortality and poor long-term prognosis. Levosimendan is a new inotropic drug that causes calcium sensitization of troponin C, thus increasing contraction force of myofilaments. The drug also causes opening of ATP-dependent potassium channels in vascular smooth muscles, which results in dilatation of veins and arteries, including cerebral arteries. To date, there have been several reports of levosimendan application in patients with SAH and neurogenic stress cardiomyopathy, and the effect of the drug on vasospasm has been previously advocated. This paper presents a case report of a 57-year-old patient with massive SAH, where levosimendan was used for reducing vasospasm. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 16% |
| Lecturer | 4 | 11% |
| Researcher | 4 | 11% |
| Librarian | 3 | 8% |
| Professor > Associate Professor | 3 | 8% |
| Other | 6 | 16% |
| Unknown | 11 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 43% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 8% |
| Nursing and Health Professions | 3 | 8% |
| Neuroscience | 2 | 5% |
| Computer Science | 2 | 5% |
| Other | 1 | 3% |
| Unknown | 10 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 June 2018.
All research outputs
#22,963,239
of 25,604,262 outputs
Outputs from Drug Design, Development and Therapy
#1,753
of 2,271 outputs
Outputs of similar age
#301,690
of 343,402 outputs
Outputs of similar age from Drug Design, Development and Therapy
#55
of 64 outputs
Altmetric has tracked 25,604,262 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,271 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,402 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.